Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Articles published by Sensorion

< Previous 1 2 3 4 Next >
Sensorion Announces Candidate Selection for GJB2 Gene Therapy Program
From Sensorion
Via Business Wire
Sensorion Appoints Khalil Barrage as Interim Chairman of the Board
From Sensorion
Via Business Wire
Sensorion Announces the Publication of Its 2022 Annual Financial Report
From Sensorion
Via Business Wire
Sensorion Reports Full-Year 2022 Financial Results and Business Update
From Sensorion
Via Business Wire
Sensorion Announces Agenda For R&D Day Showcasing Gene Therapy For Inner Ear Disease
From Sensorion
Via Business Wire
Sensorion Discloses No Exposure To Silicon Valley Bank Closure
From Sensorion
Via Business Wire
Sensorion to Participate in the 6th Annual Bioprocessing Summit Europe
From Sensorion
Via Business Wire
Sensorion Further Strengthens Leadership, Appoints David Lawrence as Chief Financial Officer
From Sensorion
Via Business Wire
Sensorion announces R&D Day focusing on its Gene Therapy programs
From Sensorion
Via Business Wire
Sensorion Will Present Two Posters at the Association for Research in Otolaryngology ARO 46th Annual MidWinter Meeting
From Sensorion
Via Business Wire
Sensorion and EVEON Collaborating to Develop an Injection System for the Delivery of Gene Therapy Treatments Into the Inner Ear
From Sensorion
Via Business Wire
Sensorion Will Take Part in a Press Conference Launching the Annual UNESCO Week of Sound
From Sensorion
Via Business Wire
Sensorion Announces First Patient Enrolled in Phase 2a Proof of Concept Clinical Trial of SENS-401 in Cisplatin-Induced Ototoxicity
From Sensorion
Via Business Wire
Sensorion Announces Its Attendance at the 41st Annual J.P. Morgan Healthcare Meeting in San Francisco
From Sensorion
Via Business Wire
Sensorion receives Orphan Drug Designation for OTOF-GT for the treatment of otoferlin gene-mediated hearing loss from the US Food and Drug Administration
From Sensorion
Via Business Wire
Sensorion Announces US FDA Grants Rare Pediatric Disease Designation to OTOF-GT for the Treatment of Otoferlin Gene-Mediated Hearing Loss
From Sensorion
Via Business Wire
Sensorion Announces Approval to Initiate amended Phase 2a Proof of Concept Clinical Trial of SENS-401 in Cisplatin-Induced Ototoxicity in France
From Sensorion
Via Business Wire
Sensorion to Present at the European Society of Gene & Cell Therapy (ESGCT) and the Gene Therapy for Rare Disorders Europe conferences in October 2022
From Sensorion
Via Business Wire
Sensorion to Participate in Various Upcoming Investor Conferences
From Sensorion
Via Business Wire
Sensorion Reports 2022 First Half Results
From Sensorion
Via Business Wire
Sensorion Announces First Patient Enrolled in Proof-of-Concept Clinical Trial of SENS-401 for Residual Hearing Preservation During Cochlear Implantation
From Sensorion
Via Business Wire
Sensorion Receives Positive Opinion for Orphan Drug Designation for OTOF-GT for the Treatment of Otoferlin Gene-Mediated Hearing Loss From the European Medicine Agency
From Sensorion
Via Business Wire
Sensorion to participate in the Inner Ear Biology Workshop in September 2022
From Sensorion
Via Business Wire
Sensorion to Present at the Gene Therapy Neurological Disorders Europe, CASSS Bioassays Symposium and Cell & Gene Therapy Summit Conferences in July 2022
From Sensorion
Via Business Wire
Sensorion Announces Approval in Australia to Initiate Proof of Concept Clinical Trial of SENS-401 for Residual Hearing Preservation During Cochlear Implantation
From Sensorion
Via Business Wire
Sensorion to Participate in the LifeSci Partners 2nd Annual Genetic Medicines Symposium on June 29, 2022
From Sensorion
Via Business Wire
Sensorion to Present at the Inner Ear Disorder Therapeutics Summit in June 2022
From Sensorion
Via Business Wire
Sensorion to Present at the Gene Therapy Development and Manufacturing Conference in June 2022
From Sensorion
Via Business Wire
Sensorion Announces Approval in France to Initiate Proof of Concept Clinical Trial of SENS-401 for Residual Hearing Preservation During Cochlear Implantation
From Sensorion
Via Business Wire
Sensorion Publishes Results of Combined General Meeting Resolutions
From Sensorion
Via Business Wire
< Previous 1 2 3 4 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.